title: Circulating adhesion molecules during kidney allograft rejection.
abstract: Adhesion molecules appear on leukocytes and endothelial cells mediating the localization and migration of leukocytes to sites of inflammation. Rejecting kidney grafts have shown an increased expression of these molecules. Recent reports have detected in serum soluble forms of adhesion molecules that could play a role in regulating inflammation. We have measured by ELISA the circulating serum levels of ICAM-1, VCAM-1 and E-selectin in: 23 controls, 33 chronic renal failure patients (CRF), 20 hemodialysis patients (HD), 17 samples from 6 patients with stable kidney graft function (STx), 25 samples from 8 patients with steroid-responsive rejection proven by biopsy, and 28 samples from 9 patients with steroid-resistant rejection and good response to OKT3. There was not a rise in cICAM-1 or cE-selectin levels during rejection compared with the steady phase before and after rejection. In the case of cVCAM-1, only the OKT3 group showed increased rejection levels (P < 0.05) that were maintained after rejection. For ICAM-1, CRF and HD groups had higher levels than the remaining groups. cVCAM-1 levels were elevated in all groups when compared with control, furthermore, OKT3 and HD groups had higher levels than the STx, CRF, or steroid-responsive groups. For cE-selectin, we only found differences between the CRF and both rejection groups. Serum creatinine correlated significantly with c-ICAM-1 and cVCAM-1 R = 0.30 and R = 0.22), but not with cE-selectin. We conclude that soluble adhesion molecules levels are not valuable markers for rejection. Patients with chronic renal failure have increased levels of adhesion molecules, which could reflect an impaired elimination.
authors.affiliation: Nephrology Services, University Hospital Marqués de Valdecilla, Santander, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Alcalde
authors.forename: J
authors.initials: J
authors.lastname: Merino
authors.forename: S
authors.initials: S
authors.lastname: Sanz
authors.forename: J A
authors.initials: JA
authors.lastname: Zubimendi
authors.forename: J C
authors.initials: JC
authors.lastname: Ruiz
authors.forename: J
authors.initials: J
authors.lastname: Torrijos
authors.forename: A L
authors.initials: AL
authors.lastname: de Francisco
authors.forename: J G
authors.initials: JG
authors.lastname: Cotorruelo
authors.forename: M
authors.initials: M
authors.lastname: López-Hoyos
authors.forename: M J
authors.initials: MJ
authors.lastname: Novo
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000097:blood*; D019040:E-Selectin; D006084:Graft Rejection / Q000097:blood* / Q000276:immunology; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use; D012016:Reference Values; D019010:Vascular Cell Adhesion Molecule-1
chemical_list: D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D019040:E-Selectin; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D008775:Methylprednisolone